Oncolytics Biotech Inc (ONCY): Capital Expenditures
$6.0K
Year ended 2025-12-31
$11.0K
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.0K | -96.6% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $174.0K | n/a | 2026-03-30, From 2024-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $6.0K | -96.6% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $123.6K | n/a |
| Processa Pharmaceuticals, Inc. (PCSA) | 2024-12-31 | $3.2K | +16.9% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $5.5K | n/a |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $109.0K | +505.6% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $59.0K | +168.2% |
| OS Therapies Inc (OSTX) | 2025-12-31 | $466.4K | n/a |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $51.3K | n/a |
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $18.2K | +334.0% |
Compare ONCY, ENSC, PCSA, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗